# Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

> **NCT07701161** · — · RECRUITING · sponsor: **Neurogen Biomarking LLC** · enrollment: 1000 (estimated)

## Conditions studied

- Alzheimer s Disease
- MCI Conversion to Dementia
- pTau217
- Biomarkers

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07701161
- **Lead sponsor:** Neurogen Biomarking LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-13
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-08-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07701161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07701161, "Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07701161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*